

## Voxzogo® (vosoritide) – Expanded indication

- On October 20, 2023, <u>BioMarin announced</u> the FDA approval of <u>Voxzogo (vosoritide)</u>, to increase linear growth in pediatric patients with achondroplasia with open epiphyses.
  - Voxzogo was previously approved for this indication in patients 5 years of age and older. This expanded indication now includes children of all ages with open growth plates.
  - This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- The use of Voxzogo for pediatric patients is supported by evidence from an adequate and wellcontrolled study in 121 pediatric patients aged 5 to 15 years with achondroplasia, pharmacokinetic data in pediatric patients aged 4.5 months to 15 years, and additional safety data in pediatric patients aged 4.4 months to < 5 years.</li>
- The recommended dosage of Voxzogo is based on the patient's actual body weight. Voxzogo is administered by subcutaneous injection once daily. Refer to the Voxzogo drug label for complete dosing information.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.